Holen Sie sich die Stockscreener-App
15.67
14.60%
-2.68
Handel nachbörslich:
15.95
0.28
+1.79%
Schlusskurs vom Vortag:
$18.35
Offen:
$18.35
24-Stunden-Volumen:
521.66K
Relative Volume:
2.59
Marktkapitalisierung:
$532.00M
Einnahmen:
$99.99M
Nettoeinkommen (Verlust:
$-21.47M
KGV:
-23.75
EPS:
-0.6597
Netto-Cashflow:
$-11.34M
1W Leistung:
-7.28%
1M Leistung:
+9.89%
6M Leistung:
+16.16%
1J Leistung:
+21.57%
1-Tages-Spanne:
$15.58
$18.67
1-Wochen-Bereich:
$15.58
$19.60
52-Wochen-Spanne:
$7.5625
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
15.67 | 622.99M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
Here's why you should add NeuroPace stock to your portfolio now - MSN
NeuroPace (NPCE) moves 6.3% higher: Will this strength last? - MSN
NPCE (Neuropace) Q4 earnings beat estimates by 48 percent yet shares fall 4.87 percent on concerns.Expert Entry Points - newser.com
Neuropace Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with 23.9% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
NeuroPace (NASDAQ:NPCE) Sets New 12-Month HighStill a Buy? - MarketBeat
ASSFN Fellows receive invitation to limited seat networking dinner by NeuroPace Inc - Traders Union
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last? - Yahoo Finance
Earnings Preview: NeuroPace to Report Financial Results Post-market on May 12 - Moomoo
NeuroPace (NPCE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
MSN Money - MSN
RNS System delivers life changing outcomes in 3 year post approval study, NeuroPace Inc reveals - Traders Union
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026 - 01net
NeuroPace Inc warns less than 5 percent seizure reduction when medications fail twice - Traders Union
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 - BioSpace
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study Results in Neurology and NAUTILUS Presentation at AAN 2026 - Investing News Network
NPCE Neuropace posts far narrower than expected Q4 2025 loss even as shares dip slightly today.Institutional Grade Picks - Newser
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NPCE Neuropace posts smaller than expected Q4 2025 loss, sending shares 2.38 percent higher in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai
Why (NPCE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NeuroPace (NASDAQ: NPCE) plans 2026 virtual vote on board and auditor - Stock Titan
NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications - Traders Union
NeuroPace Inc reports 77 percent drop in GTCs with NAUTILUS trial data - Traders Union
NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting - Traders Union
NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE - Traders Union
Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside - DirectorsTalk Interviews
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Day Trade: Is NeuroPace Inc a stock for growth or value investorsMarket Risk Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Understanding Momentum Shifts in (NPCE) - Stock Traders Daily
Forecast Cut: Will NeuroPace Inc stock benefit from M AMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Aug EndMonth: Should I hold or sell NeuroPace Inc nowWeekly Risk Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Quarterly Recap: Whats the analyst consensus on NeuroPace IncM&A Rumor & Weekly High Return Stock Forecasts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):